LENALIDOMIDE TREATMENT IN 5Q(-) SYNDROME: A SINGLE CENTER EXPERIENCE

被引：0
|
作者：
Uskudar, H. Teke [1 ]
Andic, N. [1 ]
Gunduz, E. [1 ]
Ozpolat, S. [2 ]
Aras, B. Durak [2 ]
Akay, O. [1 ]
机构：
[1] Eskisehir Osmangazi Univ, Fac Med, Hematol, Eskisehir, Turkey
[2] Eskisehir Osmangazi Univ, Fac Med, Genet, Eskisehir, Turkey
来源：
LEUKEMIA RESEARCH | 2015年 / 39卷
关键词：
D O I：
10.1016/S0145-2126(15)30198-3
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
197
引用
收藏
页码：S98 / S99
页数：2
相关论文
共 50 条
  • [21] Lenalidomide in AML: Del(5q) or who?
    Steensma, David P.
    Stone, Richard M.
    BLOOD, 2011, 118 (03) : 481 - 482
  • [22] Efficacy and safety of lenalidomide in patients with myelodysplastic syndrome with chromosome 5q deletion
    Duong, Vu H.
    Komrokji, Rami S.
    List, Alan F.
    THERAPEUTIC ADVANCES IN HEMATOLOGY, 2012, 3 (02) : 105 - 116
  • [23] Health and economic impact of the discontinuation of lenalidomide treatment in patients with myelodysplastic syndrome associated with del(5q)
    Alarcon-Payer, C.
    Salazar Bravo, M.
    Jimenez Morales, A.
    Garcia Fumero, R.
    Jurado Chacon, M.
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2019, 41 (01) : 380 - 380
  • [24] LENALIDOMIDE (LEN) IN MYELODYSPLASTIC (MDS) DEL(5Q) PATIENTS: A SINGLE INSTITUTION POPULATION-BASED EXPERIENCE
    Pelizzari, A.
    Cerqui, E.
    Schieppati, F.
    Borlenghi, E.
    Pagani, C.
    Bellotti, D.
    Rossi, G.
    HAEMATOLOGICA, 2013, 98 : 580 - 580
  • [25] Response to lenalidomide in patients with myelodysplastic syndrome with deletion 5q: clinical and cytogenetic analysis of a single centre series
    Coutinho, Rita
    Costa, Dolors
    Carrio, Ana
    Munoz, Concha
    Vidal, Ana
    Belkaid, Mohammed
    Campo, Elias
    Nomdedeu, Benet
    ANNALS OF HEMATOLOGY, 2010, 89 (10) : 1069 - 1070
  • [26] Response to lenalidomide in patients with myelodysplastic syndrome with deletion 5q: clinical and cytogenetic analysis of a single centre series
    Rita Coutinho
    Dolors Costa
    Ana Carrió
    Concha Muñoz
    Ana Vidal
    Mohammed Belkaid
    Elias Campo
    Benet Nomdedeu
    Annals of Hematology, 2010, 89 : 1069 - 1070
  • [27] Aberrant expression of the microRNA cluster in 14q32 is associated with del(5q) myelodysplastic syndrome and lenalidomide treatment
    Krejcik, Zdenek
    Belickova, Monika
    Hrustincova, Andrea
    Klema, Jiri
    Zemanova, Zuzana
    Michalova, Kyra
    Cermak, Jaroslav
    Jonasova, Anna
    Merkerova, Michaela Dostalova
    CANCER GENETICS, 2015, 208 (04) : 156 - 161
  • [28] Selective expansion of regulatory T cells during lenalidomide treatment of myelodysplastic syndrome with isolated deletion 5q
    Ekaterina Balaian
    Claudia Schuster
    Claudia Schönefeldt
    Ulrich Germing
    Detlef Haase
    Sebastian Tuve
    Rainer Ordemann
    Gerhard Ehninger
    Martin Bornhäuser
    Uta Oelschlaegel
    Brigitte Mohr
    Malte von Bonin
    Uwe Platzbecker
    Martin Wermke
    Annals of Hematology, 2016, 95 : 1805 - 1810
  • [29] Selective expansion of regulatory T cells during lenalidomide treatment of myelodysplastic syndrome with isolated deletion 5q
    Balaian, Ekaterina
    Schuster, Claudia
    Schoenefeldt, Claudia
    Germing, Ulrich
    Haase, Detlef
    Tuve, Sebastian
    Ordemann, Rainer
    Ehninger, Gerhard
    Bornhaeuser, Martin
    Oelschlaegel, Uta
    Mohr, Brigitte
    von Bonin, Malte
    Platzbecker, Uwe
    Wermke, Martin
    ANNALS OF HEMATOLOGY, 2016, 95 (11) : 1805 - 1810
  • [30] Efficacy to lenalidomide treatment and complete cytogenetic remission in a case of myelodysplastic syndrome with del(5q) and del(9q)
    Xiong, Bei
    Liu, XinYue
    Zou, Ping
    Fan, LiHua
    Chen, WanXin
    Li, WeiMing
    Liu, Lin
    LEUKEMIA RESEARCH, 2010, 34 (07) : E169 - E172
12345